Merus (MRUS) vs. Its Rivals Head to Head Review
Merus (NASDAQ: MRUS) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Merus to similar companies based on the strength of its analyst recommendations, risk, dividends, valuation, profitability, earnings and institutional ownership.
This table compares Merus and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares Merus and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Merus||$3.01 million||-$52.26 million||-2.85|
|Merus Competitors||$284.30 million||$34.29 million||133.88|
Merus’ competitors have higher revenue and earnings than Merus. Merus is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
30.1% of Merus shares are owned by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Risk and Volatility
Merus has a beta of -0.2, suggesting that its share price is 120% less volatile than the S&P 500. Comparatively, Merus’ competitors have a beta of 6.11, suggesting that their average share price is 511% more volatile than the S&P 500.
This is a breakdown of recent ratings and recommmendations for Merus and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Merus currently has a consensus target price of $30.25, indicating a potential upside of 93.79%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 45.90%. Given Merus’ stronger consensus rating and higher possible upside, equities analysts plainly believe Merus is more favorable than its competitors.
Merus competitors beat Merus on 7 of the 12 factors compared.
Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products inlcude, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as wellas MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.
Receive News & Ratings for Merus N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus N.V. and related companies with MarketBeat.com's FREE daily email newsletter.